Table 1. Clinical trials and GWAS in patients of European ancestry.
CALGB Cancer and Leukemia Group B; ICON7 International Collaboration on Ovarian Neoplasms; FOLFIRI 5-fluorouracil (400 mg/m2 and 2400 mg/m2) + leucovorin (400 mg/m2) + irinotecan (180 mg/m2); mFOLFOX6 5-fluorouracil (400 mg/m2 and 2400 mg/m2) + leucovorin (400 mg/m2) + oxaliplatin (85 mg/m2); SD standard deviation; OS overall survival; CI confidence interval; NR not reached; NE not estimated.
| Clinical Trial | CALGB 80303 | CALGB 40503 | CALGB 80405 | ICON7 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer type | Advanced pancreatic cancer | Hormone receptor-positive advanced-stage breast cancer | Locally advanced or metastatic colorectal cancer | Advanced or high-risk early-stage ovarian cancer | |||||
| Genotype platform | Illumina HumanHap550-Quad | Illumina Human OmniExpressExome-8 | Illumina HumanOmniExpress-12v1 and Illumina Human OmniExpressExome-8 | Illumina Human OmniExpressExome-8 | |||||
| Treatment | Gemcitabine 1,000 mg/m2 on days 1, 8, and 15 plus either placebo or bevacizumab 10 mg/kg on days 1 and 15 | Letrozole 2.5 mg orally/day plus either placebo or bevacizumab 15 mg/kg every 21 days | FOLFIRI or mFOLFOX6 every two weeks plus either cetuximab 400 mg/m2 on day 1, then 250 mg/m2 every week or bevacizumab 5 mg/kg every other week | Carboplatin AUC 5 or 6 and paclitaxel 286 mg/m2 or the same chemotherapy regimen plus bevacizumab 7.5 mg/kg every 3 weeks | |||||
|
| |||||||||
| Treatment arms | Bevacizumab (n=154) | Placebo (n=140) | Bevacizumab (n=105) | Placebo (n=100) | Bevacizumab (n=310) | Cetuximab (n=300) | Bevacizumab (n=212) | No Bevacizumab (n=199) | |
|
| |||||||||
| Age | Mean (SD) | 64.1 (10.2) | 63.6 (10.9) | 56.9 (11.7) | 58.5 (12.1) | 58.5 (12.2) | 59.3 (10.9) | 54.6 (9.6) | 57.7 (9.7) |
| Gender | Male (n, %) | 90 (58.4) | 69 (49.3) | 0 (0.0) | 0 (0.0) | 119 (38.4) | 112 (37.3) | 0 (0.0) | 0 (0.0) |
| Female (n, %) | 64 (41.6) | 71 (50.7) | 105 (100.0) | 100 (100.0) | 191 (61.6) | 188 (62.7) | 199 (100.0) | 212 (100.0) | |
| OS | Median (95% CI) | 5.8 (4.9–7.01) | 6.3 (5.2–7.9) | 49.2 (40.0-NE) | 46.0 (36.3–50.5) | 29.4 (26.0–32.6) | 30.1 (25.8–39.2) | NR (41.1-NE) | NR (38.8-NE) |